hepatitis C

Idenix fires off a shot in patent battle over Gilead's sofosbuvir
Fierce Biotech
Mon, 12/2/13 - 05:04 pm
Idenix
Gilead
sofosbuvir
hepatitis C
Johnson & Johnson's Real Answer To Imminent Decline In Sales Of Top-Selling Drug
Seeking Alpha
Mon, 12/2/13 - 09:45 am
JNJ
Remicade
Olysio
hepatitis C
New Hepatitis C Drug Success Should Drive Gilead Sciences In 2014
Seeking Alpha
Tue, 11/26/13 - 04:37 pm
hepatitis C
Gilead Sciences
sofosbuvir
Gilead And AbbVie Battle For Top Spot In $20 Billion Hepatitis Drug Market
Seeking Alpha
Sun, 11/24/13 - 12:24 pm
Gilead Sciences
AbbVie
hepatitis
hepatitis C
sofosbuvir
ABT-450
ABT-333
ABT-267
J&J, Medivir Win U.S. FDA Approval for Hepatitis C Pill
Bloomberg
Sat, 11/23/13 - 12:49 pm
JNJ
Medvir
hepatitis C
hepatitis
Olysio
simeprevir
Sam Waksal, A Hepatitis C Medicine And An FDA Warning Letter
Pharmalot
Fri, 11/22/13 - 10:28 am
hepatitis C
FDA
Ribasphere
Kadmon
Vertex Gains on Sale of Drug Rights to Johnson & Johnson Unit
Barron's
Wed, 11/20/13 - 04:37 pm
Vertex Pharmaceuticals
JNJ
Incivo
Janssen
hepatitis C
Don't Crown the Hepatitis C Drug Winner Just Yet
Motley Fool
Tue, 11/19/13 - 07:35 am
hepatitis C
Gilead Sciences
ABT-333
Ribavirin
ABT-450
ritonavir
ABT-267
AbbVie
AbbVie steps closer to FDA filing as first hep C PhIII delivers promising results
Fierce Biotech
Mon, 11/18/13 - 10:04 am
sofosbuvir
FDA
AbbVie
hepatitis C
How Much? A Battle Over The Cost Of The New Hepatitis C Drugs
Pharmalot
Mon, 11/11/13 - 11:40 am
hepatitis C
drug pricing
sofosbuvir
FDA
Gilead Sciences
Gilead Vs. Challengers In The Hepatitis C Race
Seeking Alpha
Thu, 11/7/13 - 09:52 am
Gilead
hepatitis C
AbbVie
Bristol-Myers Squibb
JNJ
Merck
simeprevir
sofosbuvir
daclatasvir
Bristol-Myers Squibb First to Japan in New Hepatitis C Therapy Race
Motley Fool
Wed, 11/6/13 - 10:27 am
Japan
Bristol-Myers Squibb
hepatitis C
asunaprevir
Achillion presents preclinical profile of HCV drug candidate
Yahoo/Fly on the Wall
Mon, 11/4/13 - 09:19 am
hepatitis C
Achillion
ACH-3422
New GT-1b Data from ABT-450 Containing Regimen Being Presented at The Liver Meeting
Yahoo/BusinessWire
Sun, 11/3/13 - 12:08 pm
Enanta Pharmaceuticals
ABT-450
ABT-267
hepatitis
hepatitis C
Bristol seeks Japan approval of all-oral hepatitis C treatment
Yahoo/Reuters
Sat, 11/2/13 - 11:56 am
Bristol-Myers Squibb
daclatasvir
asunaprevir
hepatitis C
hepatitis
Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Yahoo/BusinessWire
Sat, 11/2/13 - 11:40 am
MK-5172
MK-8742
hepatitis C
hepatitis
Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV
Yahoo/BusinessWire
Sat, 11/2/13 - 11:28 am
Gilead
hepatitis C
sofosbuvir
Why Idenix Could Rise Even Higher, and Challenge Gilead and Vertex
Yahoo/24-7 Wallstreet
Sat, 11/2/13 - 11:27 am
IDX20963
hepatitis C
hepatitis
The Rise and Fall of a Revolutionary Drug
Motley Fool
Wed, 10/30/13 - 10:34 am
Vertex Pharmaceuticals
Incivek
hepatitis C
Why Gilead's Sofosbuvir Is Better Than J&J's Simeprevir
Motley Fool
Tue, 10/29/13 - 09:21 am
Gilead
sofosbuvir
JNJ
hepatitis C
simeprevir

Pages